Siegfried opens a new R&D center for pharmaceutical substances in Evionnaz and its subsidiary DINAMIQS opens a new laboratory in Zurich in the field of development and manufacturing of viral vector processes

Le 19 novembre 2024, Siegfried has inaugurated its new global Research and Development (R&D) Center for Drug Substances at its site in Evionnaz, Switzerland. The 4,500m2 R&D Center houses advanced chemical and analytical facilities, state-of-the-art laboratories, and cutting-edge technologies such as flow chemistry, advanced distillation and process analytical technology, as well as new office space.

Together with the R&D Center in Zofingen, it will offer chemical process R&D and analytical development services for Siegfried's global Drug Substances network. With workspaces for over 100 highly skilled specialists and 40 new jobs created, the R&D Center strengthens Siegfried's development excellence in phase II and III supporting the company's EVOLVE+ strategy.

"The new R&D Center in Evionnaz significantly enhances our Drug Substances network and demonstrates our unwavering commitment to providing cutting-edge research and development capabilities for our customers. It will be a key element in driving development excellence as part of our EVOLVE+ strategy and represents another pivotal step in strengthening our position among the top providers in the CDMO sector." said Marcel Imwinkelried, CEO of Siegfried

Last week Siegfried reached a new milestone in its journey to strengthen its offering in the field of biologics, particularly in the growing market of cell and gene therapy. DINAMIQS, part of the Siegfried Group since May 2023, inaugurated its state-of-the-art laboratories in the Bio-Technopark in Zurich, Switzerland.

The fully equipped lab features high-end pilot-scale equipment, enabling DINAMIQS to provide clinical viral vector development, analytical and manufacturing services to meet the growing needs of the cell and gene therapy market. It is an integral part of DINAMIQS' 2,500m2 cGMP manufacturing facility for viral vectors, which is currently under construction and set to be operational by the end of 2025. This facility will host up to 1,000L production capacity for the production of viral vectors for R&D, clinical trials and commercial use under one roof.